{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:43:04Z","timestamp":1791477784922,"version":"4.3.4"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>Characterization of the conditions favouring HIV-1 low-level viraemia (LLV) during treatment is required to guide strategies for prevention and cure.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The characteristics and treatments of 171 patients experiencing a confirmed LLV of 50\u20131000 copies\/mL (PLLVs) were compared with those of 146 patients with persistently controlled viraemia. We analysed the risk factors for LLV, the parameters affecting the level of viraemia and the presence of resistance-associated mutations (RAMs). We compared outcomes for PLLVs on fully effective HAART as a function of treatment modifications.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>LLV was &amp;lt;500 copies\/mL in at least 90% of cases. A higher zenith viral load (VL) (5.27 versus 4.91 log10 copies\/mL, OR 2.23; P\u200a=\u200a0.0003), a shorter time on continuous HAART (4.3 versus 6.8 years, OR 0.88; P\u200a=\u200a0.0003) and previously detected RAMs (43% versus 23%, OR 2.42; P\u200a=\u200a0.0033) were independent predictors of LLV. NNRTIs were less frequently used in PLLVs and were associated with more stable treatment. The presence of any RAM during LLV was associated with a lower zenith VL and a higher LLV. In the absence of resistance, virological success was achieved in similar proportions of patients with and without treatment modification.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Viraemia &amp;gt;500 copies\/mL should no longer be considered to be LLV. In patients with a high zenith VL, several years on continuous HAART may be required to decrease the HIV reservoir and prevent LLV. Resistance testing is useful to detect RAMs, leading if necessary to treatment modifications. In the absence of resistance, treatment changes seemed dispensable.<\/jats:p><\/jats:sec>","DOI":"10.1093\/jac\/dkv099","type":"journal-article","created":{"date-parts":[[2015,4,29]],"date-time":"2015-04-29T01:02:22Z","timestamp":1430269342000},"page":"2347-2353","source":"Crossref","is-referenced-by-count":32,"title":["Low-level HIV-1 viraemia in patients on HAART: risk factors and management in clinical practice"],"prefix":"10.1093","volume":"70","author":[{"given":"Marc","family":"Wirden","sequence":"first","affiliation":[{"name":"1 \u00a0INSERM, UMR S_1136, Institut Pierre Louis d'Epid\u00e9miologie et de Sant\u00e9 Publique, F-75013 Paris, France"},{"name":"2 \u00a0Sorbonne Universit\u00e9s, UPMC Univ Paris 06, UMR_S 1136, Institut Pierre Louis d'Epid\u00e9miologie et de Sant\u00e9 Publique, F-75013 Paris, France"},{"name":"3 \u00a0AP-HP, Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re, Service de Virologie, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eve","family":"Todesco","sequence":"additional","affiliation":[{"name":"1 \u00a0INSERM, UMR S_1136, Institut Pierre Louis d'Epid\u00e9miologie et de Sant\u00e9 Publique, F-75013 Paris, France"},{"name":"2 \u00a0Sorbonne Universit\u00e9s, UPMC Univ Paris 06, UMR_S 1136, Institut Pierre Louis d'Epid\u00e9miologie et de Sant\u00e9 Publique, F-75013 Paris, France"},{"name":"3 \u00a0AP-HP, Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re, Service de Virologie, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc-Antoine","family":"Valantin","sequence":"additional","affiliation":[{"name":"1 \u00a0INSERM, UMR S_1136, Institut Pierre Louis d'Epid\u00e9miologie et de Sant\u00e9 Publique, F-75013 Paris, France"},{"name":"2 \u00a0Sorbonne Universit\u00e9s, UPMC Univ Paris 06, UMR_S 1136, Institut Pierre Louis d'Epid\u00e9miologie et de Sant\u00e9 Publique, F-75013 Paris, France"},{"name":"4 \u00a0AP-HP, Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re, Service de Maladies Infectieuses, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidonie","family":"Lambert-Niclot","sequence":"additional","affiliation":[{"name":"1 \u00a0INSERM, UMR S_1136, Institut Pierre Louis d'Epid\u00e9miologie et de Sant\u00e9 Publique, F-75013 Paris, France"},{"name":"2 \u00a0Sorbonne Universit\u00e9s, UPMC Univ Paris 06, UMR_S 1136, Institut Pierre Louis d'Epid\u00e9miologie et de Sant\u00e9 Publique, F-75013 Paris, France"},{"name":"3 \u00a0AP-HP, Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re, Service de Virologie, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Simon","sequence":"additional","affiliation":[{"name":"5 \u00a0AP-HP, Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re, Service de M\u00e9decine Interne, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruxandra","family":"Calin","sequence":"additional","affiliation":[{"name":"1 \u00a0INSERM, UMR S_1136, Institut Pierre Louis d'Epid\u00e9miologie et de Sant\u00e9 Publique, F-75013 Paris, France"},{"name":"2 \u00a0Sorbonne Universit\u00e9s, UPMC Univ Paris 06, UMR_S 1136, Institut Pierre Louis d'Epid\u00e9miologie et de Sant\u00e9 Publique, F-75013 Paris, France"},{"name":"4 \u00a0AP-HP, Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re, Service de Maladies Infectieuses, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Tubiana","sequence":"additional","affiliation":[{"name":"1 \u00a0INSERM, UMR S_1136, Institut Pierre Louis d'Epid\u00e9miologie et de Sant\u00e9 Publique, F-75013 Paris, France"},{"name":"2 \u00a0Sorbonne Universit\u00e9s, UPMC Univ Paris 06, UMR_S 1136, Institut Pierre Louis d'Epid\u00e9miologie et de Sant\u00e9 Publique, F-75013 Paris, France"},{"name":"4 \u00a0AP-HP, Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re, Service de Maladies Infectieuses, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Peytavin","sequence":"additional","affiliation":[{"name":"6 \u00a0AP-HP, Groupe Hospitalier X Bichat-C Bernard, laboratoire de toxicologie, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Katlama","sequence":"additional","affiliation":[{"name":"1 \u00a0INSERM, UMR S_1136, Institut Pierre Louis d'Epid\u00e9miologie et de Sant\u00e9 Publique, F-75013 Paris, France"},{"name":"2 \u00a0Sorbonne Universit\u00e9s, UPMC Univ Paris 06, UMR_S 1136, Institut Pierre Louis d'Epid\u00e9miologie et de Sant\u00e9 Publique, F-75013 Paris, France"},{"name":"4 \u00a0AP-HP, Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re, Service de Maladies Infectieuses, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Calvez","sequence":"additional","affiliation":[{"name":"1 \u00a0INSERM, UMR S_1136, Institut Pierre Louis d'Epid\u00e9miologie et de Sant\u00e9 Publique, F-75013 Paris, France"},{"name":"2 \u00a0Sorbonne Universit\u00e9s, UPMC Univ Paris 06, UMR_S 1136, Institut Pierre Louis d'Epid\u00e9miologie et de Sant\u00e9 Publique, F-75013 Paris, France"},{"name":"3 \u00a0AP-HP, Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re, Service de Virologie, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Genevieve","family":"Marcelin","sequence":"additional","affiliation":[{"name":"1 \u00a0INSERM, UMR S_1136, Institut Pierre Louis d'Epid\u00e9miologie et de Sant\u00e9 Publique, F-75013 Paris, France"},{"name":"2 \u00a0Sorbonne Universit\u00e9s, UPMC Univ Paris 06, UMR_S 1136, Institut Pierre Louis d'Epid\u00e9miologie et de Sant\u00e9 Publique, F-75013 Paris, France"},{"name":"3 \u00a0AP-HP, Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re, Service de Virologie, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,4,28]]},"reference":[{"key":"2022020121044065800_DKV099C1","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/nm0696-625","article-title":"HIV viral load markers in clinical practice","volume":"2","author":"Saag","year":"1996","journal-title":"Nat Med"},{"issue":"Suppl 1","key":"2022020121044065800_DKV099C2","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1016\/j.jcv.2011.09.015","article-title":"Evolution in the sensitivity of quantitative HIV-1 viral load tests","volume":"52","author":"Cobb","year":"2011","journal-title":"J Clin Virol"},{"key":"2022020121044065800_DKV099C3","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/QCO.0b013e32834ef5d9","article-title":"Low-level viraemia on HAART: significance and management","volume":"25","author":"Doyle","year":"2012","journal-title":"Curr Opin Infect Dis"},{"key":"2022020121044065800_DKV099C4","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1128\/AAC.00076-14","article-title":"Significance and clinical management of persistent low-level viremia and very-low-level viremia in HIV-1-infected patients","volume":"58","author":"Ryscavage","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2022020121044065800_DKV099C5","volume-title":"Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents","author":"Panel on Antiretroviral Guidelines for Adults and Adolescents","year":"2014"},{"key":"2022020121044065800_DKV099C6","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1001\/jama.2012.7961","article-title":"Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel","volume":"308","author":"Thompson","year":"2012","journal-title":"JAMA"},{"issue":"Suppl 1","key":"2022020121044065800_DKV099C7","first-page":"1","article-title":"British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (Updated November 2013. All changed text is cast in yellow highlight)","volume":"15","author":"Williams","year":"2014","journal-title":"HIV Med"},{"key":"2022020121044065800_DKV099C8","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1177\/135965350601100605","article-title":"Design issues in initial HIV-treatment trials: focus on ACTG A5095","volume":"11","author":"Ribaudo","year":"2006","journal-title":"Antivir Ther"},{"key":"2022020121044065800_DKV099C9","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1086\/592693","article-title":"Increased detectability of plasma HIV-1 RNA after introduction of a new assay and altered specimen-processing procedures","volume":"47","author":"Rebeiro","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2022020121044065800_DKV099C10","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1086\/498025","article-title":"Transient viremia in HIV-infected patients and use of plasma preparation tubes","volume":"41","author":"Stosor","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2022020121044065800_DKV099C11","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1128\/JCM.02034-09","article-title":"Coamplification of HIV-1 proviral DNA and viral RNA in assays used for quantification of HIV-1 RNA","volume":"48","author":"Wan","year":"2010","journal-title":"J Clin Microbiol"},{"key":"2022020121044065800_DKV099C12","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/infdis\/jir208","article-title":"Relationship between residual plasma viremia and the size of HIV proviral DNA reservoirs in infected individuals receiving effective antiretroviral therapy","volume":"204","author":"Chun","year":"2011","journal-title":"J Infect Dis"},{"key":"2022020121044065800_DKV099C13","doi-asserted-by":"crossref","first-page":"9625","DOI":"10.1128\/JVI.79.15.9625-9634.2005","article-title":"Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: expression of archival virus and replication of virus","volume":"79","author":"Tobin","year":"2005","journal-title":"J Virol"},{"key":"2022020121044065800_DKV099C14","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1093\/cid\/cir936","article-title":"Plasma HIV-1 RNA detection below 50 copies\/mL and risk of virologic rebound in patients receiving highly active antiretroviral therapy","volume":"54","author":"Doyle","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2022020121044065800_DKV099C15","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1093\/cid\/ciu020","article-title":"Reliability and clinical relevance of the HIV-1 drug resistance test in patients with low viremia levels","volume":"58","author":"Santoro","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2022020121044065800_DKV099C16","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/infdis\/jir353","article-title":"Antiretroviral drug resistance in HIV-1-infected patients experiencing persistent low-level viremia during first-line therapy","volume":"204","author":"Taiwo","year":"2011","journal-title":"J Infect Dis"},{"key":"2022020121044065800_DKV099C17","doi-asserted-by":"crossref","first-page":"e50065","DOI":"10.1371\/journal.pone.0050065","article-title":"Increased risk of virologic rebound in patients on antiviral therapy with a detectable HIV load &lt;48 copies\/mL","volume":"7","author":"Henrich","year":"2012","journal-title":"PLoS One"},{"key":"2022020121044065800_DKV099C18","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1093\/cid\/cit529","article-title":"Virologic failure following persistent low-level viremia in a cohort of HIV-positive patients: results from 12 years of observation","volume":"57","author":"Laprise","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2022020121044065800_DKV099C19","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1097\/00002030-200205030-00010","article-title":"Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy","volume":"16","author":"Aleman","year":"2002","journal-title":"AIDS"},{"key":"2022020121044065800_DKV099C20","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1093\/cid\/cir933","article-title":"Plasma HIV-1 RNA levels during antiretroviral therapy: how low is low enough?","volume":"54","author":"Gandhi","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2022020121044065800_DKV099C21","article-title":"Virologic failure endpoint definition in clinical trials: is using HIV-1 RNA threshold &lt;200 copies\/mL better then &gt;50 copies\/mL? An analysis of ACTG studies","author":"Ribaudo"},{"key":"2022020121044065800_DKV099C22","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1093\/jac\/dkt484","article-title":"Markers associated with persisting low-level viraemia under antiretroviral therapy in HIV-1 infection","volume":"69","author":"Vancoillie","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2022020121044065800_DKV099C23","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1177\/135965350801300707","article-title":"Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy","volume":"13","author":"Geretti","year":"2008","journal-title":"Antivir Ther"},{"key":"2022020121044065800_DKV099C24","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/QAD.0b013e3283427de3","article-title":"Higher efficacy of nevirapine than efavirenz to achieve HIV-1 plasma viral load below 1 copy\/ml","volume":"25","author":"Haim-Boukobza","year":"2011","journal-title":"AIDS"},{"key":"2022020121044065800_DKV099C25","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1086\/499364","article-title":"Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study","volume":"42","author":"Ribaudo","year":"2006","journal-title":"Clin Infect Dis"},{"key":"2022020121044065800_DKV099C26","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMoa074609","article-title":"Class-sparing regimens for initial treatment of HIV-1 infection","volume":"358","author":"Riddler","year":"2008","journal-title":"N Engl J Med"},{"key":"2022020121044065800_DKV099C27","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1097\/QAD.0000000000000203","article-title":"HIV drug resistance detected during low-level viraemia is associated with subsequent virologic failure","volume":"28","author":"Swenson","year":"2014","journal-title":"AIDS"},{"key":"2022020121044065800_DKV099C28","doi-asserted-by":"crossref","first-page":"e9390","DOI":"10.1371\/journal.pone.0009390","article-title":"Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection","volume":"5","author":"Archin","year":"2010","journal-title":"PLoS One"},{"key":"2022020121044065800_DKV099C29","doi-asserted-by":"crossref","first-page":"9403","DOI":"10.1073\/pnas.0903107106","article-title":"Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy","volume":"106","author":"Dinoso","year":"2009","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/70\/8\/2347\/42355475\/jac_70_8_2347.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/70\/8\/2347\/42355475\/jac_70_8_2347.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T12:00:42Z","timestamp":1651838442000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/70\/8\/2347\/811472"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,28]]},"references-count":29,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2015,4,28]]},"published-print":{"date-parts":[[2015,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkv099","relation":{},"ISSN":["1460-2091","0305-7453"],"issn-type":[{"value":"1460-2091","type":"electronic"},{"value":"0305-7453","type":"print"}],"subject":[],"published-other":{"date-parts":[[2015,8]]},"published":{"date-parts":[[2015,4,28]]}}}